Category: Clinical Trial Update Region: North America · United States Company: Novartis Consumer Health Inc

Novartis Phase Iii Canopy A Study Evaluating Canakinumab As Adjuvant Treatment In Nsclc Fails To Meet Primary Endpoint

By, Admin 1 min read
Share
Novartis Phase Iii Canopy A Study Evaluating Canakinumab As Adjuvant Treatment In Nsclc Fails To Meet Primary Endpoint
Novartis Announced That The Phase Iii Canopy-A Study Evaluating Adjuvant Treatment With Canakinumab (Acz885), An Inhibitor Of Interleukin-1Beta (Il-1

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!